KRYS241220C210000
- 4.00
- +2.98+292.16%
Krystal Biotech Newsroom
Some Confidence Is Lacking In Krystal Biotech, Inc.'s (NASDAQ:KRYS) P/S
Krystal Biotech, Inc. (NASDAQ:KRYS) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Unusual Options Activity: C, DAL and Others Attract Market Bets, C V/OI Ratio Reaches 519.3
Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
Krystal Q3 Earnings and Sales Top Estimates, Vyjuvek Gains Traction
Krystal Biotech Is Maintained at Neutral by Citigroup
Express News | HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $206 to $221
Q3 2024 Krystal Biotech Inc Earnings Call
Krystal Biotech Faces Challenges in Scaling VYJUVEK Production Amid Regulatory Hurdles
Earnings Call: Krystal Biotech Reports Robust Q3 2024 Results
Krystal Biotech Price Target Raised to $212 From $208 at Chardan
Krystal Biotech, Inc. (KRYS) Q3 2024 Earnings Call Transcript Summary
Krystal Biotech's Strong Financial Performance and Strategic Advancements Drive Buy Rating
Krystal Biotech | 10-Q: Q3 2024 Earnings Report
Krystal Biotech | 8-K: Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates
Krystal Biotech Reports Q3 EPS 91c, Consensus 90c
Krystal Biotech GAAP EPS of $0.91 Beats by $0.01, Revenue of $83.84M Beats by $0.73M
Krystal Biotech 3Q Product Rev $83.8M >KRYS
Earnings Flash (KRYS) KRYSTAL BIOTECH Reports Q3 Revenue $83.8M